跳至主要内容
临床试验/NCT05105477
NCT05105477终止不适用

Hypotension Prediction Index (HPI) Software Guided Hemodynamic Management for Noncardiac Surgery Patients - Blood Pressure Trial (National PI: Kamal Maheshwari, MD, MPH)

Edwards Lifesciences21 个研究点 分布在 1 个国家目标入组 407 人开始时间: 2021年11月17日最近更新:
适应症

试验速览

阶段
不适用
状态
终止
发起方
入组人数
407
试验地点
21
主要终点
A Composite of 30-day Moderate-to-severe Perfusion Related Postoperative Complications.

研究概览

简要总结

A multicenter, randomized comparison of intraoperative hemodynamic management with or without a protocolized strategy utilizing Hypotension Prediction Index (HPI) software guidance during moderate-to-high-risk noncardiac surgery.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Sequential
主要目的
Prevention
盲法
Double (Participant, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Signed informed consent
  • Age >18 years
  • ASA Physical Status > 2
  • Noncardiac surgery with expected surgery duration > 2 hours (example include: orthopedic, spine, urology, and general surgery)
  • Planned blood pressure monitoring with an arterial line catheter;
  • General anesthesia;

排除标准

  • Participating in another interventional Trial;
  • Contraindication to arterial blood pressure monitoring;
  • Subjects with a physical site area too limited for proper Sensor placement
  • Serum creatine > 175 μmol/L (>2.0 mg/dL) or CKD stage > 3A
  • Scheduled for intracranial surgery with permissive hypotension;
  • Patient who is confirmed to be pregnant and/or nursing mothers;
  • Patients with an intra-aortic balloon pump (IABP) or ventricular assist device(s);
  • Have a condition that precludes routine or tight blood pressure management such as surgeon request for relative hypotension;
  • Emergency surgery;
  • Require beach-chair positioning;
  • Scheduled for cardiac surgeries
  • Have previously participated in the SMART-BP trial.

结局指标

主要结局

A Composite of 30-day Moderate-to-severe Perfusion Related Postoperative Complications.

时间窗: From post non-cardiac surgery to 30 days.

A composite of 30-day moderate-to-severe perfusion related postoperative complications.

次要结局

未报告次要终点

研究者

发起方
Edwards Lifesciences
申办方类型
Industry
责任方
Sponsor

研究点 (21)

Loading locations...

相似试验